ILMN Stock Analysis — Illumina
Sector: Healthcare
AI Verdict
Illumina trades at 29.6x next year's earnings for just 2.7% EPS growth—you're paying up for a narrative the numbers don't yet support, even with its entrenched sequencing moat.
Competitive Moat
Illumina dominates the DNA sequencing market with proprietary sequencing-by-synthesis technology and a locked-in installed base of labs reliant on its consumables. This creates high switching costs and recurring revenue from consumables, making its position defensible even as new entrants emerge.
Summary
Illumina's stock has doubled in a year, but earnings growth is barely moving while the valuation stays rich.
Where It Stands
With a 104.33% 1-year return, an RSI of 82.2 (deeply overbought), and a forward P/E of 29.6x versus the healthcare median of 22x, Illumina is trading at a premium despite slow growth.
Key Metrics
- RSI: 82.2 — Overbought
- Trailing P/E: 30.4x
- Forward P/E: 29.6x
- PEG Ratio: 58.87
- Earnings Growth: +0.0%
- Revenue Growth: +0.0%
- Market Cap: $25.4B
- 1-Year Return: 104.33%
- 52-Week High: $172.49
- 52-Week Low: $78.79
Analyst Consensus
17 Buy · 8 Hold · 3 Sell (28 analysts)
Bull Case
Bulls point to the 2.7% forward EPS growth and 29.6x forward P/E as a bet that Illumina's sequencing platform moat will eventually reignite higher growth.
Bear Case
If the P/E drops to the sector median of 22x, that's a 26% downside from current levels, and the 82.2 RSI signals a high risk of a near-term pullback.
Catalyst to Watch
Watch for new product launches or regulatory updates that could materially accelerate EPS growth above the current 2.7% consensus.